Eli Lilly and Company (NYSE:LLY) Shares Bought by Waterfront Wealth Inc.

Waterfront Wealth Inc. grew its position in Eli Lilly and Company (NYSE:LLY) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,157 shares of the company’s stock after acquiring an additional 24 shares during the quarter. Waterfront Wealth Inc.’s holdings in Eli Lilly and Company were worth $674,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of LLY. Lipe & Dalton acquired a new stake in Eli Lilly and Company during the 4th quarter worth $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at about $27,000. Retirement Group LLC boosted its stake in shares of Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after buying an additional 35 shares during the period. Cornerstone Planning Group LLC purchased a new position in shares of Eli Lilly and Company during the second quarter worth about $33,000. Finally, Legacy Financial Group LLC purchased a new position in shares of Eli Lilly and Company during the third quarter worth about $35,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 0.1 %

Eli Lilly and Company stock traded down $1.10 during trading on Thursday, hitting $749.67. The company’s stock had a trading volume of 262,023 shares, compared to its average volume of 3,047,469. The stock’s fifty day moving average is $764.03 and its 200 day moving average is $657.67. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a 1-year low of $367.35 and a 1-year high of $800.78. The stock has a market capitalization of $712.31 billion, a price-to-earnings ratio of 129.46, a P/E/G ratio of 1.63 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.09 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 12.52 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the sale, the insider now owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on LLY shares. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Finally, BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.